PRRT2 and cancer: By downregulating the level of ROS, activating the protein kinase C (PKC) pathway, regulating the mitogen-activated protein kinase (MAPK) signaling pathway, regulating autophagy, inducing the apoptosis of cancer cells, inhibiting the biological activity of cancer cell proliferation, and regulating the expression of pathway-related proteins to exert immunomodulatory effects (Reyes-Farias and Carrasco-Pozo, 2019; Wang et al., 2019; Xu et al., 2019; Wei et al., 2024), there are certain tumor immune effects.